An Index Case of Concomitant Tumoral and Ichthyosiform Mycosis Fungoides–Like Presentation of Chronic Adult T-cell Leukemia/Lymphoma Associated With Upregulation of TOX

We present a 68-year-old human T-cell lymphotropic virus type 1 seropositive female with a mild peripheral blood atypical lymphocytosis who had indurated nodules on her hands of 2 years duration and a new scaly ichthyosiform eruption on her lower extremities. Histopathologic examination of the hand biopsy revealed coalescing nodules of large atypical noncerebriform lymphocytes with focal areas of epidermotropism. Phenotypically, the infiltrate was positive for β-F1, CD2, CD4, CD5, CD7, Foxp3, and CD25. In both biopsies, there was striking upregulation of TOX (thymocyte selection–associated high mobility group box factor) in the nuclei of neoplastic cells. The second biopsy taken from the ichthyotic patch on the patient's left leg showed a subtle pattern of epidermal infiltration by atypical noncerebriform lymphocytes and a distinct compact scale consistent with the clinical picture of ichthyosis. The histopathologic appearance was that of a yet undescribed ichthyosiform mycosis fungoides–like presentation of chronic ATLL. In addition, the observed upregulation of nuclear TOX may play an oncogenic role in ATLL. The course to date in this patient has been relatively indolent, although the patients believe that large cell transformation could portend more aggressive disease.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Original Study Source Type: research

Related Links:

Authors: Fang W, Peng ZL, Dai YJ, Wang DL, Huang P, Huang HP Abstract Realgar and (-)-Epigallocatechin-3-gallate (EGCG) are natural medicines that inhibit cancer cell growth, resulting in inhibition of formation and development of tumors. The anticancer effects of realgar and EGCG were greatly improved following formulation as nanoparticles. EGCG has received increased attention as a drug carrier. The aim of this study was to prepare a new nanomedicine, (EGCG-RNPs), in which encapsulated nano-realgar. EGCG-RNPs were prepared by coprecipitation and characterized by transmission electron microscopy (TEM), differentia...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Authors: Morabito F, Recchia AG, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M Abstract Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases.Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversib...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-ba...
Source: Surgical Oncology Clinics of North America - Category: Surgery Authors: Source Type: research
Authors: Nishikawa T, Oka T, Shioyama W, Kashimoto K, Yasui T, Oboshi M, Kamada R, Fujita M Abstract Venous thromboembolism occurs in prothrombotic states, such as malignancy. To prevent fatal pulmonary thromboembolism, an indwelling inferior vena cava (IVC) filter is considered in addition to anticoagulation therapy. We herein report a case of fracture of a retrievable IVC filter in a malignant lymphoma patient. One of the filter arms was fractured and fixed to the IVC wall after one year. Since dislocation of the fractured arm was assessed correctly using three-dimensional computed tomography, we were able to ret...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion: MTHFR rs4846049 polymorphism may be associated with increased risk of childhood with ALL and MTHFR mRNA expression. PMID: 31737664 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Publication date: Available online 19 November 2019Source: Fish &Shellfish ImmunologyAuthor(s): Qingying Liu, Minglei Xu, Zhenzhu Sun, Huaqun Ye, Kangsen Mai, Xiaohong Tan, Cuiyun Zou, Shu Chen, Ningning Su, Yuanyuan Zhou, Leling Chen, Chaoxia YeAbstractThe purpose of the present study was to explore the impaired anti-bacteria ability in immune organs and immune systems of obscure puffer induced by chronic dietary phosphorus (P) deficiency. Fish were fed diets supplemented with 6 g/kg P (P6) and 0 g/kg P (P0) respectively for 15 weeks, and lower final body weight, feed intake, weight gain, whole body P content and ...
Source: Fish and Shellfish Immunology - Category: Biology Source Type: research
Condition:   Acute Myeloid Leukemia Intervention:   Other: Sample collection Sponsors:   Centre Hospitalier Universitaire de Besancon;   Centre Hospitalier Universitaire Dijon;   Etablissement Français du Sang Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Hepatic Veno-Occlusive Disease;   Nephroblastoma;   Acute Lymphoblastic Leukemia Intervention:   Other: Blood test for genetic analysis Sponsor:   University Hospital, Angers Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Glasdegib;   Drug: Gemtuzumab Ozogamicin Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Acute Myeloid Leukemia Intervention:   Drug: rhTPO Sponsor:   Huihan Wang Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Cancer & Oncology | Chronic Leukemia | Dermatology | Ichthyosis | Leukemia | Lymphoma | Skin | Skin Biopsy | Study